Výsledky vyhledávání - "Angiolillo, Dj"

Akademický článek

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar

Autor: Cho JR, Rollini F, Franchi F, Ferrante E, Angiolillo DJ

Publikováno v: Vascular Health and Risk Management, Vol 2014, Iss default, Pp 177-188 (2014)

Jung Rae Cho, Fabiana Rollini, Francesco Franchi, Elisabetta Ferrante, Dominick J Angiolillo University of Florida College of Medicine – Jacksonville, Jacksonville, FL, USA Abstract: Platelet activation with subsequent aggregation is a complex proc

Externí odkaz: https://doaj.org/article/41da4fa1f12741a78c947da2d6eb948c

Zobrazit plný text záznamu

A Comprehensive Review of the Pleiotropic Effects of Ticagrelor

Autor: Triska, J, Maitra, N, Deshotels, MR, Haddadin, F, Angiolillo, DJ, Vilahur, G, Jneid, H, Atar, D, Birnbaum, Y

Publikováno v: CARDIOVASCULAR DRUGS AND THERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Aims This review summarizes the findings of preclinical studies evaluating the pleiotropic effects of ticagrelor. These include attenuation of ischemia-reperfusion injury (IRI), inflammation, adverse cardiac remodeling, and atherosclerosis. In doing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::da7c9a6f13591a18001e634d3ef6ecf3
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12226

Zobrazit plný text záznamu

Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention

Autor: Bhatt, DL, Kaski, JC, Delaney, S, Alasnag, M, Andreotti, F, Angiolillo, DJ, Ferro, A, Gorog, DA, Lorenzatti, AJ, Mamas, M, McNeil, J, Nicolau, JC, Steg, PG, Tamargo, J, Tan, D, Valgimigli, M

Aims\ud Choosing an antiplatelet strategy in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) at high bleeding risk (HBR), undergoing post-percutaneous coronary intervention (PCI), is complex. We used a unique open-source app

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::a517bace8e2639a809c6846668023d2b
https://openaccess.sgul.ac.uk/id/eprint/113249/7/1-s2.0-S016752732100824X-main.pdf

Zobrazit plný text záznamu

Antithrombotic therapy in diabetes: which, when, and for how long?

Autor: Ajjan, RA, Kietsiriroje, N, Badimon, L, Vilahur, G, Gorog, DA, Angiolillo, DJ, Russell, DA, Rocca, B, Storey, RF

Publikováno v: EUROPEAN HEART JOURNAL
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)

Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::969cd0bb4ea85c1249eedfcd330b539d
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5560

Zobrazit plný text záznamu

Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel

Publikováno v: Journal of the American College of Cardiology, 76(12), 1468-1483. Elsevier Inc.

Investigating the balance of risk for thrombotic and bleeding events after percutaneous coronary intervention (PCI) is especially relevant for patients at high bleeding risk (HBR). The Academic Research Consortium for HBR recently proposed a consensu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c4d4d239fcdeae99dcdcf44041459857
https://pubmed.ncbi.nlm.nih.gov/32943165

Zobrazit plný text záznamu

Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial

Autor: Tomaniak, M, Chichareon, P, Onuma, Y, Deliargyris, EN, Takahashi, K, Kogame, N, Modolo, R, Chang, CC, Rademaker-Havinga, T, Storey, RF, Dangas, GD, Bhatt, DL, Angiolillo, DJ, Hamm, C, Valgimigli, M, Windecker, S, Steg, PG, Vranckx, P, Serruys, PW, Bertrand, OF, Plante, S, Van Geuns, RJ, Hofma, SH, Royaards, KJ, Slagboom, T, Suryapranata, H, Umans, VAWM, Rensing, B, van der Harst, P, Magro, M, Barbato, E, Aminian, A, Benit, E, Janssens, L, Vrolix, M, Buysschaert, I, Carrie, D, Barraud, P, Teiger, E, Koning, R, Farzin, B, Morelle, JF, Isaaz, K, Maillard, L, Abdellaoui, M, Brunel, P, Angioi, M, Lantelme, P, Sabate, M, Gonzalez-Trevilla, AA, Cequier, A, Iiguez, A, Penaranda, AS, Miguel, CM, Diaz, JF, Antolin, RAH, Goicolea, J, Ribeiro, VG, da Silva, PC, Ferreira, RC, Almeida, M, Ungi, I, Merkely, B, Fontos, G, Horvath, I, Koszegi, Z, Jambrik, Z, Edes, I, Jozsef, F, Colombo, A, Bolognese, L, Ferrario, M, Tumscitz, C, Dominici, M, Curello, S, Roffi, M, Eeckhout, E, Moccetti, T, Moschovitis, A, Leibundgut, G, Huber, K, Frey, B, Delle Karth, G, Friedrich, G, Steinwender, C, Zweiker, R, Stables, R, Anderson, R, Chowdhary, S, Garg, S, Hildick-Smith, D, Fath-Ordoubadi, F, Oldroyd, KG, Galasko, G, Kukreja, N, Zaman, A, Subkovas, E, Curzen, N, Hoole, S, Talwar, S, Walsh, S, Adlam, D, Cotton, J, Holmvang, L, Ottesen, MM, Buszman, P, Zurakowski, A, Galuszka, G, Prokopczuk, J, Zmudka, K, Jasionowicz, P, Mlodziankowski, A, Liebetrau, C, Naber, CK, Neumann, FJ, Schchinger, V, Seidler, T, Ibrahim, K, Zrenner, B, Gori, T, Werner, N, Akin, I, Geisler, T, vom Dahl, J, Haude, M, Eitel, I, Krackhardt, F, Jung, W, Neto, PAL, Sousa, A, Quintella, EF, Leandro, S, Botelho, R, Raffel, C, Barlis, P, Hai, KT, Ong, P, Petrov, I, Konteva, M, Velchev, V, Gelev, V, Tonev, G, Valkov, V, Vassilev, D, Trendafilova-Lazarova, D

Publikováno v: JAMA Cardiology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Key PointsQuestionWhat are the benefits and risks of continuing aspirin in addition to P2Y12 receptor inhibition with ticagrelor among patients with acute coronary syndrome between 1 month and 12 months after percutaneous coronary intervention? Findi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::8e99cfdec67e6c8c3d495fbed8c58795
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13737

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání